Cargando…

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

BACKGROUND: The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of disease-modifying therapies (DMTs) in preclinical and early AD (mild cognitive impa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Assunção, Sheila Seleri, Sperling, Reisa A., Ritchie, Craig, Kerwin, Diana R., Aisen, Paul S., Lansdall, Claire, Atri, Alireza, Cummings, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017027/ https://www.ncbi.nlm.nih.gov/pubmed/35440022 http://dx.doi.org/10.1186/s13195-022-00984-y

Ejemplares similares

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

Trends in Healthcare Resource Use Preceding Diagnosis of Alzheimer's Disease Dementia
por: Abbass, Ibrahim M., et al.
Publicado: (2023)

Determining clinically meaningful decline in preclinical Alzheimer disease
por: Insel, Philip S., et al.
Publicado: (2019)

Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary
por: Cummings, Jeffrey
Publicado: (2023)

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview
por: Aisen, P.S., et al.
Publicado: (2020)

Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review
por: Rentz, Dorene M, et al.
Publicado: (2013)

APOE effects on regional tau in preclinical Alzheimer’s disease
por: Young, Christina B., et al.
Publicado: (2023)

On the path to 2025: understanding the Alzheimer’s disease continuum
por: Aisen, Paul S., et al.
Publicado: (2017)

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
por: Bateman, Randall J, et al.
Publicado: (2011)

Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
por: Walter, S., et al.
Publicado: (2020)

Pro: Can biomarkers be gold standards in Alzheimer's disease?
por: Sperling, Reisa, et al.
Publicado: (2010)

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
por: Bateman, Randall J., et al.
Publicado: (2022)

The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years
por: Walter, S., et al.
Publicado: (2020)

Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease
por: Samaroo, Aubryn, et al.
Publicado: (2021)

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5
por: Papp, Kathryn V., et al.
Publicado: (2017)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease
por: Cohen, S., et al.
Publicado: (2022)

Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis
por: Liss, J. L., et al.
Publicado: (2021)

Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease
por: Papp, Kathryn V., et al.
Publicado: (2021)

Functional MRI Assessment of Task-Induced Deactivation of the Default Mode Network in Alzheimer’s Disease and At-Risk Older Individuals
por: Pihlajamäki, Maija, et al.
Publicado: (2009)

Large-Scale Functional Brain Network Abnormalities in Alzheimer’s Disease: Insights from Functional Neuroimaging
por: Dickerson, Bradford C., et al.
Publicado: (2009)

Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease
por: Jutten, Roos J., et al.
Publicado: (2022)

Computerized cognitive practice effects in relation to amyloid and tau in preclinical Alzheimer's disease: Results from a multi‐site cohort
por: Young, Christina B., et al.
Publicado: (2023)

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
por: Doody, Rachelle S, et al.
Publicado: (2015)

Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer’s disease
por: Guzmán-Vélez, Edmarie, et al.
Publicado: (2022)

Function and clinical meaningfulness of treatments for mild Alzheimer's disease
por: Siemers, Eric, et al.
Publicado: (2016)

Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease
por: Norton, Daniel J., et al.
Publicado: (2020)

Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease
por: Roe, Catherine M., et al.
Publicado: (2018)

Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease
por: Müller, Stephan, et al.
Publicado: (2017)

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
por: Hanseeuw, Bernard J., et al.
Publicado: (2019)

Prevention approaches in a preclinical canine model of Alzheimer’s disease: benefits and challenges
por: Davis, Paulina R., et al.
Publicado: (2014)

Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer’s disease
por: Hampton, Olivia L., et al.
Publicado: (2020)

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
por: Rafii, Michael S., et al.
Publicado: (2023)

Alzheimer's disease therapeutic research: the path forward
por: Aisen, Paul S
Publicado: (2009)

Q & A: The Alzheimer's disease neuroimaging initiative
por: Aisen, Paul S
Publicado: (2011)

Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates
por: Wessels, Alette M., et al.
Publicado: (2022)

Assessing the Clinical Meaningfulness of the Alzheimer’s Disease Composite Score (ADCOMS) Tool
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease
por: Jack, Clifford R., et al.
Publicado: (2018)

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
por: Hansson, Oskar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ev8gobd079dbfvinnkojqpvpb3